Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Share-based Compensation data on record, last reported at $3.9 million in Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 21.88% to $3.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.2 million, a 4.66% decrease, with the full-year FY2025 number at $12.5 million, down 14.33% from a year prior.
  • Share-based Compensation reached $3.9 million in Q1 2026 per FULC's latest filing, up from $3.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for FULC hit a ceiling of $4.3 million in Q2 2024 and a floor of $2.5 million in Q4 2024.
  • A 5-year average of $3.5 million and a median of $3.4 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 85.58% in 2022, then plummeted 33.82% in 2025.
  • Tracing FULC's Share-based Compensation over 5 years: stood at $3.3 million in 2022, then increased by 5.44% to $3.4 million in 2023, then dropped by 28.18% to $2.5 million in 2024, then increased by 23.78% to $3.1 million in 2025, then grew by 25.9% to $3.9 million in 2026.
  • Business Quant data shows Share-based Compensation for FULC at $3.9 million in Q1 2026, $3.1 million in Q4 2025, and $3.4 million in Q3 2025.